paclitaxel has been researched along with Malignant Mesothelioma in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Barraja, P; Carbone, A; Cilibrasi, V; Cirrincione, G; Cominetti, D; Diana, P; Lopergolo, A; Montalbano, A; Parrino, B; Pennati, M; Spanò, V; Zaffaroni, N; Zuco, V | 1 |
| Aerts, JGJV; Brandt-Kerkhof, ARM; Burger, JWA; Dietz, MV; Guchelaar, NAD; Koolen, SLW; Madsen, EVE; Mathijssen, RHJ; van Kooten, JP; Verhoef, C | 1 |
| Ma, J; Zhang, S | 1 |
| Alessandri, G; Alfieri, R; Bonelli, M; Coccé, V; Flammini, L; Frati, C; Gianni, A; La Monica, S; Lagrasta, CA; Paino, F; Pessina, A; Petrella, F | 1 |
| Alessandri, G; Alfieri, R; Bonelli, M; Coccè, V; Doneda, L; Giannì, A; La Monica, S; Lagrasta, CA; Martegani, E; Paino, F; Pessina, A; Petrella, F; Roncoroni, L; Sordi, V | 1 |
| Chu, NQ; Colby, A; Colson, YL; de Forcrand, C; Grinstaff, MW; Liu, R; Padera, RF | 1 |
| Stuart, OA; Sugarbaker, PH | 1 |
| Duan, J; Huang, T; Zhang, J; Zhang, Q; Zhao, W | 1 |
| Antonoff, MB | 1 |
| Catalano, P; Colby, A; Colson, YL; Grinstaff, MW; Hofferberth, SC; Lei, H; Liu, R; Tevis, KM | 1 |
| Alessandri, G; Brini, AT; Coccè, V; Masia, C; Milani, M; Parati, E; Pentimalli, F; Pessina, A; Petrella, F; Salè, EO; Sisto, F; Spaggiari, L | 1 |
2 trial(s) available for paclitaxel and Malignant Mesothelioma
| Article | Year |
|---|---|
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
Topics: Adult; Humans; Mesothelioma, Malignant; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2022 |
Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Paclitaxel; Postoperative Period | 2014 |
9 other study(ies) available for paclitaxel and Malignant Mesothelioma
| Article | Year |
|---|---|
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Isoindoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Peritoneal Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
Topics: Female; Humans; Ki-67 Antigen; Mesothelioma, Malignant; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies | 2022 |
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice.
Topics: Animals; Cell Line, Tumor; Heterografts; Humans; Mesothelioma; Mesothelioma, Malignant; Mice; Paclitaxel | 2023 |
Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma.
Topics: Cell Line, Tumor; Humans; Mesenchymal Stem Cells; Mesothelioma; Mesothelioma, Malignant; Paclitaxel | 2023 |
Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Models, Animal; Disease Progression; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Nanoparticles; Paclitaxel; Pleural Neoplasms; Pneumonectomy; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Hyperthermic Intraperitoneal Chemotherapy; Male; Mesothelioma, Malignant; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Into another dimension: Assessing novel therapeutics in a more lifelike microenvironment.
Topics: Antineoplastic Agents, Phytogenic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Nanoparticles; Paclitaxel; Pinocytosis | 2015 |
Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carboxylic Acids; Cell Line, Tumor; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Ethanol; Excipients; Fluorescent Dyes; Glycerol; Humans; Kinetics; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Microscopy, Confocal; Nanomedicine; Nanoparticles; Paclitaxel; Pinocytosis; Rhodamines; Spheroids, Cellular; Technology, Pharmaceutical | 2015 |
Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Humans; Lung Neoplasms; Mesenchymal Stem Cells; Mesothelioma; Mesothelioma, Malignant; Paclitaxel; Pemetrexed | 2017 |